GleamWall
中文EN

TLX Telix Pharmaceuticals Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 2007191 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY55.6%
TTM net income YoY-121.2%
TTM EPS YoY-121.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin53.1%
Operating margin3.7%
Net margin-0.9%
FCF margin-5.3%
EBITDA margin6.4%

Returns

ROE-1.9%
ROA-0.7%
ROIC (approx.)5.0%
Asset turnover0.76x

Leverage & solvency

Liabilities / assets64.3%
Debt / equity0.98x
Current ratio1.43x
Interest coverage164.51x

Cash quality & payout

Operating cash flow / net income2.43x
Accruals ratio1.0%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$803.79M$516.55M
Cost of revenue$377.36M$180.39M
Gross profit$426.44M$336.16M
R&D expense$171.25M$127.93M
SG&A expense$95.79M$85.32M
Operating income$29.78M$55.18M
Interest expense$181,000$64,000
Pretax income-$5.27M$37.91M
Income tax$1.86M$4.23M
Net income-$7.12M$33.69M
EBITDA$51.28M$60.03M
EPS (basic)-0.020.10
EPS (diluted)-0.020.10
Weighted avg. shares (diluted)337.88M345.19M
Balance sheet
Cash & equivalents$141.87M$440.00M
Receivables$129.20M$86.93M
Inventory$37.08M$23.62M
Current assets$330.28M$570.12M
PP&E, netmay include right-of-use assets (IFRS)$58.66M$27.84M
Goodwill$198.99M$66.59M
Intangibles$592.82M$257.86M
Total assets$1.16B$940.38M
Current liabilities$231.62M$205.09M
Short-term debt$13.11M$11.76M
Long-term debt$391.91M$341.81M
Total debt$405.02M$353.57M
Total liabilities$748.61M$587.44M
Shareholders' equity$415.38M$352.94M
Net debt$263.16M-$86.42M
Cash flow statement
Operating cash flow-$17.29M$27.49M
Capital expenditure$25.69M$9.12M
Free cash flow-$42.98M$18.37M
Investing cash flow-$285.92M-$86.69M
Financing cash flow-$3.72M$416.79M
Depreciation & amortization$21.51M$4.85M
Stock-based compensation$19.35M$12.93M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.